Date: 2015-11-25
Type of information: Private placement
Company: Spark Therapeutics (USA - PA)
Investors:
Amount:
Funding type: private placement
Planned used:
Others: * On December 15, 2015, Spark Therapeutics announced the pricing of an underwritten public offering of 3,000,000 shares of its common stock at a public offering price of $47.00 per share, before underwriting discounts. The offering consists of 2,000,000 shares being sold by Spark and 1,000,000 shares being sold by The Children’s Hospital of Philadelphia Foundation (“CHOP”), resulting in aggregate net proceeds of approximately $88.4 million to Spark and approximately $44.2 million to CHOP, after deducting underwriting discounts and before offering expenses. In addition, Spark and CHOP have granted the underwriters of the offering an option for a period of 30 days to purchase up to an additional 450,000 shares at the public offering price, less the underwriting discount. Spark will not receive any proceeds from the sale of shares by CHOP. The offering is expected to close on or about December 21, 2015, subject to satisfaction of customary closing conditions. A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on December 15, 2015. * On December 14, 2015, Spark Therapeutics announced that it has commenced an underwritten public offering of 3,000,000 shares of its common stock. The offering consists of 2,000,000 shares being offered by Spark and 1,000,000 shares being offered by The Children’s Hospital of Philadelphia Foundation(CHOP). In addition, Spark and CHOP are expected to grant the underwriters of the offering an option for a period of 30 days to purchase up to an additional 450,000 shares at the public offering price, less the underwriting discount. Spark will not receive any proceeds from the sale of shares by CHOP. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed. * On November 25, 2015, Spark Therapeutics announced the filing of a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to a proposed public offering of shares of its common stock. A portion of the shares to be sold in the offering will be sold by Spark and a portion will be sold by The Children’s Hospital of Philadelphia (“CHOP”) Foundation. Spark will not receive any proceeds from the shares sold by the CHOP Foundation. The number of shares to be sold and the allocation of the shares between Spark and the CHOP Foundation have not yet been determined. J.P. Morgan Securities LLC is acting as lead book-running manager for the offering. A registration statement relating to these securities has been filed with the Securities and Exchange Commission, but has not yet become effective.
Therapeutic area:
